-transparent.png){kind=logo}
Expression of the early genes of the human immunodeficiency virus type-I (HIV-1) genome is under the control of a trans-activator (Tat) protein. HIV-1 Tat action requires binding to TAR (trans-activation responsive element), an RNA sequence located at the 5'-end of all lentiviral mRNAs. We used various spectroscopic methods to investigate conformational changes on HIV-1 TAR binding to the HIV-1 (32-72) Tat peptide BP1. It comprises the RNA binding region and binds specifically to TAR. We conclude from our experiments that the regular A-form of the TAR RNA is slightly distorted towards the B-form when bound to BP1. Thus, the major groove is widened and the binding of BP1 facilitated. BP1 presumably adopts an extended conformation when binding to TAR and may fit well into the TAR major groove.
A U Metzger, and
T Schindler, and
D Willbold, and
M Kraft, and
C Steegborn, and
A Volkmann, and
R W Frank, and
P Rosch
December 1998,
Journal of biomolecular structure & dynamics,
A U Metzger, and
T Schindler, and
D Willbold, and
M Kraft, and
C Steegborn, and
A Volkmann, and
R W Frank, and
P Rosch
November 1997,
Nucleic acids research,
A U Metzger, and
T Schindler, and
D Willbold, and
M Kraft, and
C Steegborn, and
A Volkmann, and
R W Frank, and
P Rosch
January 2017,
Current pharmaceutical design,
A U Metzger, and
T Schindler, and
D Willbold, and
M Kraft, and
C Steegborn, and
A Volkmann, and
R W Frank, and
P Rosch
December 2018,
Proceedings of the National Academy of Sciences of the United States of America,
A U Metzger, and
T Schindler, and
D Willbold, and
M Kraft, and
C Steegborn, and
A Volkmann, and
R W Frank, and
P Rosch
September 2018,
Scientific reports,
A U Metzger, and
T Schindler, and
D Willbold, and
M Kraft, and
C Steegborn, and
A Volkmann, and
R W Frank, and
P Rosch
May 2002,
Biochemistry,
A U Metzger, and
T Schindler, and
D Willbold, and
M Kraft, and
C Steegborn, and
A Volkmann, and
R W Frank, and
P Rosch
July 2000,
The Journal of biological chemistry,
A U Metzger, and
T Schindler, and
D Willbold, and
M Kraft, and
C Steegborn, and
A Volkmann, and
R W Frank, and
P Rosch
January 2006,
Bioconjugate chemistry,
A U Metzger, and
T Schindler, and
D Willbold, and
M Kraft, and
C Steegborn, and
A Volkmann, and
R W Frank, and
P Rosch
December 2005,
Current drug targets. Infectious disorders,
A U Metzger, and
T Schindler, and
D Willbold, and
M Kraft, and
C Steegborn, and
A Volkmann, and
R W Frank, and
P Rosch
October 2021,
Viruses,
